February 27, 2019
2 min watch

VIDEO: J&J lowers Lipiflow activator price to improve access to technology

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

NEW ORLEANS – Joseph Boorady, OD, FAAO, vice president of ocular surface for Johnson & Johnson Vision, announced a price cut on the activators for its Lipiflow device.

“Our hope is that this lower activator cost makes the Lipiflow MGD [meibomian gland dysfunction] treatment more accessible and lays the foundation for changing the standard of care for MGD,” he said.

Boorady also shared positive clinical study results for the technology.